**Table 4:** Treatment options and outcomes of patients.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variables** | **Survivor**  **n = 30** | **Ex**  **n = 24** | **HR** | **%95CI** | **p** |
| Initial treatment |  |  |  |  |  |
| R-CHOP | 13 (43.3) | 13 (54.2) | ref |  |  |
| RCHOP/RDHAP | 8 (26.7) | 4 (16.7) | 0.75 | 0.24-2.31 | 0.617 |
| R-HyperCVAD | 3 (10.0) | 1 (4.2) | 0.55 | 0.07-4.26 | 0.568 |
| R-Bendamustine | 1 (3.3) | 0 (.0) | 0.986 | 0.01-1.08 | 0.999 |
| R-CVP | 2 (6.7) | 4 (16.7) | 2.27 | 0.73-7.06 | 0.157 |
| R-COEP | 2 (6.7) | 1 (4.2) | 0.81 | 0.10-6.34 | 0.843 |
| R-chlorambucil | 1 (3.3) | 1 (4.2) | 0.83 | 0.11-6.35 | 0.853 |
| Response to after initial treatment |  |  |  |  |  |
| CR | 20 (66.7) | 6 (25.0) | ref |  |  |
| PR | 7 (23.3) | 4 (16.7) | 2.31 | 0.62-8.60 | 0.214 |
| SD | - | 4 (16.7) | 10.34 | 2.64-40.49 | 0.001\* |
| PD | 3 (10.0) | 10 (41.7) | 7.00 | 2.35-20.82 | < 0.001\* |
| Second-line treatment |  |  |  |  |  |
| Not-given | 24 (80.0) | 7 (29.2) | ref |  |  |
| R-HyperCVAD | 1 (3.3) | 3 (12.5) | 6.87 | 1.70-27.74 | 0.007\* |
| R-ICE | - | 1 (4.2) | 14.64 | 1.62-132.10 | 0.017\* |
| R-DHAP | 1 (3.3) | 2 (8.3) | 4.43 | 0.88-22.38 | 0.071 |
| R-BENDA | 2 (6.7) | 7 (29.2) | 5.70 | 1.91-17.02 | 0.002\* |
| BORİD | 2 (6.7) | 3 (12.5) | 3.06 | 0.76-12.26 | 0.114 |
| HİGH-DOZ-MTX | - | 1 (4.2) | 23.09 | 2.44-218.65 | 0.006\* |
| Response to second line treatment |  |  |  |  |  |
| CR | 4 (66.7) | - | - |  |  |
| PR | 2 (33.3) | 11 (64.7) | - |  |  |
| SD | - | 2 (11.8) | - |  |  |
| PD | - | 4 (23.5) | - |  |  |
| Otolog BMT after the initial treatment |  |  |  |  |  |
| (-) | 10 (33.3) | 21 (87.5) | ref |  |  |
| (+) | 20 (66.7) | 3 (12.5) | 0.13 | 0.04-0.43 | 0.001\* |

Categorical variables were shown as number (%).

\*p < 0.05 shows statistical significance.

**Abbreviations:** HR: Hazard ratio, CI: Confidence interval, R-CHOP: (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone), RCHOP/RDHAP: (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone/rituxiamb, dexamethasone, high-dose cytarabine, cisplatin), R-HyperCVAD : (rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine), R-CVP: (rituximab, cyclophosphamide, prednisone.), R-COEP: , ……….. CR: Complet remision, PR: Partial remision, SD: Stabale disease, PD: Progressive disease.